Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 2Leukemia, Myeloid 2Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 627pembrolizumab 506Paclitaxel 455Gemcitabine 439Carboplatin 438Cisplatin 421Radiotherapy 382fludarabine 368Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 246Fluorouracil 229Dexamethasone 225Specimen Handling 224Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Biopsy 198Temozolomide 197Ipilimumab 197fludarabine phosphate 195Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Injections 171Cetuximab 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × RO6839921 × Clear all
NCT02098967 2018-05-17

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Hoffmann-La Roche

Phase 1 Completed
68 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms

NCT01677780 2017-07-07

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Hoffmann-La Roche

Phase 1 Completed
11 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡